BGD Stock Overview
Biogened S.A. develops, produces, and distributes pharmaceutical products in Poland.
Biogened S.A. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||zł14.10|
|52 Week High||zł16.00|
|52 Week Low||zł8.00|
|1 Month Change||-8.44%|
|3 Month Change||11.91%|
|1 Year Change||62.07%|
|3 Year Change||78.48%|
|5 Year Change||12.89%|
|Change since IPO||-64.75%|
Recent News & Updates
Is Biogened (WSE:BGD) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|BGD||PL Pharmaceuticals||PL Market|
Return vs Industry: BGD exceeded the Polish Pharmaceuticals industry which returned -0.4% over the past year.
Return vs Market: BGD exceeded the Polish Market which returned -33.1% over the past year.
|BGD Average Weekly Movement||12.1%|
|Pharmaceuticals Industry Average Movement||5.5%|
|Market Average Movement||6.1%|
|10% most volatile stocks in PL Market||11.7%|
|10% least volatile stocks in PL Market||3.8%|
Stable Share Price: BGD is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: BGD's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
Biogened S.A. develops, produces, and distributes pharmaceutical products in Poland. The company offers dermo-cosmetic products under the Dermedic brand. It also exports its products.
Biogened S.A. Fundamentals Summary
|BGD fundamental statistics|
Is BGD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BGD income statement (TTM)|
|Cost of Revenue||zł26.06m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 14, 2022
|Earnings per share (EPS)||1.49|
|Net Profit Margin||5.06%|
How did BGD perform over the long term?See historical performance and comparison